219 related articles for article (PubMed ID: 34518197)
21. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
22. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
[TBL] [Abstract][Full Text] [Related]
23. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
24. Quantitative Multiplexed Analysis of Indoleamine 2,3-Dioxygenase (IDO) and Arginase-1 (ARG1) Expression and Myeloid Cell Infiltration in Colorectal Cancer.
Elomaa H; Härkönen J; Väyrynen SA; Ahtiainen M; Ogino S; Nowak JA; Lau MC; Helminen O; Wirta EV; Seppälä TT; Böhm J; Mecklin JP; Kuopio T; Väyrynen JP
Mod Pathol; 2024 Apr; 37(4):100450. PubMed ID: 38369188
[TBL] [Abstract][Full Text] [Related]
25. Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.
Weis-Banke SE; Lisle TL; Perez-Penco M; Schina A; Hübbe ML; Siersbæk M; Holmström MO; Jørgensen MA; Marie Svane I; Met Ö; Ødum N; Madsen DH; Donia M; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36316062
[TBL] [Abstract][Full Text] [Related]
26. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor β neutralization finely tunes macrophage phenotype in elastase-induced abdominal aortic aneurysm and is associated with an increase of arginase 1 expression in the aorta.
Raffort J; Lareyre F; Clément M; Moratal C; Jean-Baptiste E; Hassen-Khodja R; Burel-Vandenbos F; Bruneval P; Chinetti G; Mallat Z
J Vasc Surg; 2019 Aug; 70(2):588-598.e2. PubMed ID: 30792060
[TBL] [Abstract][Full Text] [Related]
28. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase.
Sharda DR; Yu S; Ray M; Squadrito ML; De Palma M; Wynn TA; Morris SM; Hankey PA
J Immunol; 2011 Sep; 187(5):2181-92. PubMed ID: 21810604
[TBL] [Abstract][Full Text] [Related]
29. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
30. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
32. Ginseng-derived nanoparticles reprogram macrophages to regulate arginase-1 release for ameliorating T cell exhaustion in tumor microenvironment.
Lv Y; Li M; Weng L; Huang H; Mao Y; Yang DA; Wei Q; Zhao M; Wei Q; Rui K; Han X; Fan W; Cai X; Cao P; Cao M
J Exp Clin Cancer Res; 2023 Nov; 42(1):322. PubMed ID: 38012650
[TBL] [Abstract][Full Text] [Related]
33. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
34. Tumor Cells Modulate Macrophage Phenotype in a Novel In Vitro Co-Culture Model of the NSCLC Tumor Microenvironment.
Park JV; Chandra R; Cai L; Ganguly D; Li H; Toombs JE; Girard L; Brekken RA; Minna JD
J Thorac Oncol; 2022 Oct; 17(10):1178-1191. PubMed ID: 35798240
[TBL] [Abstract][Full Text] [Related]
35. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
38. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
39. The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
Weis-Banke SE; Hübbe ML; Holmström MO; Jørgensen MA; Bendtsen SK; Martinenaite E; Carretta M; Svane IM; Ødum N; Pedersen AW; Met Ö; Madsen DH; Andersen MH
Oncoimmunology; 2020 Jun; 9(1):1771142. PubMed ID: 32923127
[TBL] [Abstract][Full Text] [Related]
40. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
